Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• WEE1 and ATR kinases are key regulators of the cell cycle and DNA damage response.
• Inhibitors targeting WEE1 and ATR are being explored as novel cancer treatments.
• Understanding the combined effects of WEE1 and ATR inhibition is crucial for optimizing therapeutic strategies.

Purpose of the Study:

• To investigate the potential advantages of simultaneously inhibiting WEE1 and ATR kinases in cancer treatment.
• To evaluate the efficacy of combined WEE1 and ATR inhibition across different cancer cell lines.
• To assess the impact of combined inhibition on cell viability, DNA damage, and response to radiation.

Main Methods:

• Utilized WEE1 inhibitor (MK1775) and ATR inhibitor (VE822) in U2OS osteosarcoma and lung cancer cell lines (H460, A549, H1975, SW900).
• Assessed effects on cell viability, CDK activity, ATR activation, and DNA damage.
• Investigated combined treatment effects with and without radiation.

Main Results:

• WEE1 inhibition consistently reduced CDK phosphorylation and increased CDK activity, leading to ATR activation.
• Combined WEE1 and ATR inhibition showed variable effects on cell viability, not fully overcoming resistance to WEE1 inhibition alone.
• Synergistic DNA damage was observed in U2OS cells but not in lung cancer cells; synergy was reduced with radiation co-treatment.

Conclusions:

• Combined WEE1 and ATR inhibition may be beneficial in certain cancer types, but efficacy varies significantly between cell lines.
• Monotherapy with WEE1 or ATR inhibitors might be preferable when combined with radiotherapy.
• Further research is needed to identify predictive biomarkers for response to combined WEE1 and ATR inhibition.